Hepatitis B virus (HBV) has been implicated as a potential trigger of hepatic steatosis although molecular mechanisms involved in the pathogenesis of HBV-associated hepatic steatosis still remain elusive. Our prior work has revealed that the expression level of liver fatty acid binding protein 1 (FABP1), a key regulator of hepatic lipid metabolism, was elevated in HBV-producing hepatoma cells. In this study, the effects of HBV X protein (HBx) mediated FABP1 regulation on hepatic steatosis and the underlying mechanism were determined. mRNA and protein levels of FABP1 were measured by quantitative RT-PCR (qPCR) and Western blotting. HBx-mediated FABP1 regulation was evaluated by luciferase assay, coimmunoprecipitation, and chromatin immunoprecipitation. Hepatic lipid accumulation was measured by using Oil-Red-O staining and the triglyceride level. It was found that expression of FABP1 was increased in HBV-producing hepatoma cells, the sera of HBV-infected patients, and the sera and liver tissues of HBV-transgenic mice. 
H
epatitis B virus (HBV) infection is a serious health problem worldwide, causing acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma (1) . Emerging evidence from epidemiological and experimental studies suggests that chronic HBV infection, as well as HCV infection, is associated with hepatic steatosis (2, 3) . The frequency of hepatic steatosis in subjects with a chronic HBV infection ranges from 27 to 51% (4) . Furthermore, HBV X protein (HBx) is known to cause hepatic lipid deposition by inhibiting the secretion of apolipoprotein B (5) . A previous report showed that the increased HBx expression can cause lipid accumulation in hepatocytes, likely mediated by sterol regulatory element binding protein 1 and peroxisome proliferator-activated receptor ␥ (PPAR␥) (4) . The molecular mechanism by which HBV induces the pathogenesis of hepatic steatosis remains elusive. Using fluorescent two-dimensional difference gel electrophoresis and matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis, we found that the protein level of liver fatty acid binding protein (L-FABP or FABP1) in HBVproducing cells was significantly increased compared to that in control cells (6) .
Liver fatty acid binding protein belongs to a multigene FABP family of 14-to 15-kDa cytoplasmic proteins involved in the uptake, transport, and metabolism of cellular long-chain fatty acids and other lipid ligands (7) . The human FABP1 gene is localized in the centromeric p12-q11 region of chromosome 2 (8) . FABP1 is found abundantly in the cytosol of liver parenchymal cells (9, 10) and represents ca. 0.2% of the total cytosolic proteins in the human hepatoblastoma cell line HepG2 (11) . Similar to its family members, FABP1 plays a central role in intracellular fatty acid transport and utilization (12) and is also involved in the modulation of mitosis (13) , cell growth, and differentiation (14) . Studies in HepG2 cells suggested that the overexpression of FABP1 markedly increased the rate of fatty acid uptake. In contrast, fatty acid uptake significantly decreased following FABP1 antisense RNA expression (15) . FABP1 gain-of-function experiments also revealed an increase in fatty acid uptake and lipoprotein secretion from rat hepatoma cells (16) . Moreover, the Thr94Ala mutation in the FABP1 gene, which was supposed to abolish the binding of fatty acid, led to decreased triglycerides compared to the wild-type cells when incubated with extracellular fatty acids (17) . In a transgenic mouse model, ablation of FABP1 gene impaired the ability of the liver to efficiently import and transfer fatty acids into glycerolipid biosynthesis resulting in a reduction of hepatic triglyceride (TG) accumulation (18) . These changes were not due to an inability to upregulate fatty acid oxidation or TG synthesis but rather resulted from decreased rates of hepatic fatty acid uptake and trafficking in the face of short-term (48-h) mobilization of adipose TG stores and increased fatty acid availability (18) . The germ line FABP1 Ϫ/Ϫ mice exhibited decreased hepatic triglyceride content with altered fatty acid uptake kinetics (18) . Interestingly, FABP1
Ϫ/Ϫ mice fed a high-saturated-fat, high-cholesterol "Western" diet were protected against diet-induced obesity and hepatic steatosis, reflecting an alteration in the kinetics of saturated fatty acid utilization (19, 20) . Proteomic screens showed FABP1 to be overexpressed in obese subjects with simple steatosis, along with paradoxically decreased expression in the progressive versus mild forms of nonalcoholic steatohepatitis (20) .
Given the key role of FABP1 in lipid metabolism and its potential influence on metabolic disorders and the fact that subjects with chronic HBV infection frequently develop hepatic steatosis, we sought to determine whether FABP1 was involved in HBVassociated hepatic steatosis and to explore the molecular mechanism responsible for the regulation of FABP1 by HBx.
MATERIALS AND METHODS
Cell lines and patients. HepG2 (HB-8065; American Type Culture Collection [ATCC], Manassas, VA), Huh7 (JCRB0403; Japan), and Hep3B (HB-8064; ATCC) cells were maintained in Dulbecco modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% (vol/ vol) fetal bovine serum (FBS) (Invitrogen). HepG2.2.15 cells (CRL-11997; ATCC) harboring four copies of HBV-DNA were cultured in modified Eagle medium (Invitrogen) with G418 (Invitrogen) at 380 g/ ml. HepG2-HBV3 cell line harboring 1.2 unit lengths of the HBV genome and control HepG2-RepSal1 cell line (6) were maintained in DMEM supplemented with 10% FBS and hygromycin B (Roche Diagnostics, GmbH, Mannheim, Germany) at 250 g/ml.
A total of 150 patients with chronic hepatitis B were collected from the Fuzhou Hospital for Infectious Diseases for FABP1 detection in serum by enzyme-linked immunosorbent assay (ELISA). These patients were positive for HBsAg, HBeAg, anti-HBc, and HBV-specific DNA in serum. The HBV viral load was quantified by using an HBV diagnostic kit (Abbott Laboratories, Chicago, IL) according to the manufacturer's instructions. No antiviral drugs were administered before the blood samples were drawn. A total of 30 normal non-HBV-infected sera were obtained as controls. The clinical section of the research was reviewed and ethically approved by the Institutional Ethics Committee of Fujian Medical University (Fuzhou, China). All patients had given informed and written consent.
Plasmids, oligonucleotide siRNA transfection, and generation of recombinant adenoviruses and lentiviruses. pGL3B-255, pGL3B-255HNF3␤mut, and pGL3B-255C/EBP␣mut were constructed as previously described (21) . pGL3B-255PPAR␣mut and pGL3B-255mut (which included triple binding site mutations for HNF3␤, C/EBP␣, and PPAR␣) were synthesized chemically by the Sangon Biotech (Shanghai, China). HNF3␤ and C/EBP␣ small interfering RNAs (siRNAs) were described in our earlier study (21) . PPAR␣ siRNA mix and FABP1 siRNA mix were obtained from Santa Cruz Biotechnology, and a nontargeting siRNA was used as a negative control (NC). pRep-HBV (harboring 1.2 unit lengths of the HBV genome) and control plasmid pRep-Sal were described previously (6) . The pRep-HBV-X(-) mutation plasmid, which contains an stop codon at HBx codon 8 (CAA to UAA), was generated by site-specific mutagenesis as described previously (22) . DNA transfection was carried out using Lipofectamine 2000 (Invitrogen), and siRNA transfections were performed by use of Lipofectamine RNAiMAX (Invitrogen).
HBx-overexpressing adenovirus (Ad-HBx) and empty control (Ad-GFP) were generated using the AdEasy XL system (Stratagene, CA) as we previously described (23) . HepG2, Huh7, and Hep3B cells were seeded in six-well plates at a density of 5 ϫ 10 5 per well and infected with recombinant adenoviruses at a multiplicity of infection (MOI) of 10, 100, or 200 or the indicated doses, respectively. Cell culture supernatants were collected, and cells were harvested at 72 h postinfection. Recombinant lentivirus LV-FABP1-shRNA containing short hairpin RNA (shRNA) against mouse FABP1 was constructed by GeneChem Co., Ltd. (Shanghai, China), the target sequence was 5=-GTCAGAAATCGTGCATGAA-3=. The negative-control lentiviruses LV-GFP were provided by GeneChem.
Animal experiments. Male, age-matched (6 to 8 weeks old) HBV (HBV-Tg) or HBx ϩ/-transgenic mice (HBx-Tg) and their wild-type (WT) littermates (24) were used in this study. Mice were housed in humidity-and temperature-controlled rooms, with free access to food and water. High-fat-diet (HFD)-induced obese mice were given an HFD (Diet Research, USA) for 8 weeks, while the control mice were fed a normal diet (ND). Control lentivirus (LV-GFP) or LV-FABP1-shRNA recombinant lentivirus (5 ϫ 10 7 infectious lentivirus particles per mouse) were delivered by hydrodynamic tail vein injection to mice (25) . Blood samples were obtained by heart puncture at time of sacrifice. The hepatic index was calculated as liver wet weight/body weight. Liver tissues were extracted, immediately snap-frozen using liquid nitrogen, and stored at Ϫ80°C until analyzed. The animal study was approved by the Fujian Medical University Institutional Animal Care and Use Committee (IACUC). The IACUC protocol number for the study is M00186.
In vitro model of cellular steatosis. Sodium palmitate (catalog no. P9767) and sodium oleate (catalog no. O7501) were obtained from Sigma-Aldrich (St. Louis, MO). Fat-overloading induction of cells was performed mainly according to previously established methods (26) , where HepG2 cells at 80% confluence were exposed to saturated (palmitate) and unsaturated (oleate) long-chain free fatty acid (FFA) mixtures at a ratio of 2:1. Fatty acid-free bovine serum albumin (BSA) was used as a control. To assess the influence of FABP1 knockdown on cellular steatosis, cells were treated with FFA mixture after 48 h of siRNA-FABP1 transfection. After incubation with the FFA mixture, cellular lipid accumulation was measured using Oil-Red-O staining and the triglyceride level.
Determination of cellular fat content and triglyceride level. OilRed-O staining was performed on liver sections and HepG2 cells using standard procedures as previously described (27) . The triglyceride content was determined using a commercially available kit (Sigma-Aldrich) according to the manufacturer's instructions and normalized to the protein content by BCA assay (Pierce, Rockford, IL).
Liver morphology. Liver tissues were fixed in 4% formalin and embedded in paraffin according to standard methods. Paraffin-embedded tissues were sectioned (5 m) and stained with hematoxylin and eosin (H&E) for morphological analysis.
qPCR and Western blot analysis. Total RNA and protein were extracted from HepG2 cell lysates or mouse liver tissues for gene expression analysis.
qPCR was performed with the ABI StepOne real-time PCR system (Applied Biosystems, Foster City, CA) and a SYBR Premix Ex Taq kit (TaKaRa) in accordance with the manufacturer's instructions. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) served as an internal control. The forward and reverse primers used were 5=-CAAGTTCACCATC ACCGCTG-3= and 5=-ATTATGTCGCCGTTGAGTTCG-3= for FABP1 and 5=-TGCACCACCAACTGCTTAGC-3= and 5=-AGCTCAGGGATGA CCTTGCC-3= for GAPDH.
Western blot analysis was performed using anti-FABP1 (1:1,000 dilution, HPA028275; Sigma), anti-Flag M2 (1:1,000 dilution; Sigma), anti-HNF3␤ (sc-6554; 1:500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), anti-C/EBP␣ (sc-61, 1:500 dilution; Santa Cruz Biotechnology), anti-PPAR␣ (sc-9000; Santa Cruz Biotechnology), or anti-␤-actin (1:4,000 dilution; Sigma) and then probed with alkaline phosphatase (AP)-conjugated appropriate secondary antibody and chemiluminescence detection. Immunoreactive protein bands were visualized by adding CDP STAR reagents (Roche). Intensities of band signals were quantified using the densitometric software Quantity One (Bio-Rad, Hercules, CA).
Luciferase assay. HepG2 cells were plated in a 12-well culture plate and transiently cotransfected with 0.2 g of promoter reporter plasmids or pGL3-Basic (Promega, Madison, WI)/well and 0.1 g of the pRL-TK plasmid (Promega) containing the Renilla luciferase gene used for internal normalization/well. After 48 h, the cells were harvested, and a total of 20 g of cell lysate was used for the detection of intracellular luciferase activity according to the recommendations of the Promega Corporation. Luminescence measurement was carried out on a luminometer (Orion II microplate luminometer; Berthold Detection Systems, Germany). All assays were performed at least in triplicate.
Coimmunoprecipitation assay. Lysates from HepG2 cells were immunoprecipitated with anti-FLAG M2 agarose (Sigma) or HNF3␤, C/EBP␣, and PPAR␣ antibodies and protein A/G agarose (Santa Cruz Biotechnology) at 4°C overnight. The immune complexes were eluted and subjected to Western blot analysis with the respective antibodies. ChIP assay. Chromatin immunoprecipitation (ChIP) assay was performed according to Abcam's X-ChIP protocol. For immunoprecipitation, sonicated cell lysates were incubated with anti-HNF3␤, anti-C/ EBP␣, anti-PPAR␣, or anti-Flag M2 (the same amount of normal IgG as control) antibodies for protein-DNA binding detection. Bound target DNA fractions were analyzed by PCR with the paired primers 5=-CATTT CGTGGGGTGCGGAGA-3 (sense) and 5=-AAGAACAGGATGGGCACA GC-3= (antisense), which amplified the region from nucleotides Ϫ136 to Ϫ251 (region 1 [R1]) containing HNF3␤ and C/EBP␣ binding sites, and the paired primers 5=-GCTGTGCCCATCCTGTTCTT-3= (sense) and 5=-GGGGCTCCCTTCCCTTCGAA-3= (antisense), which amplified the region from nucleotides Ϫ36 to Ϫ155 (region 2 [R2]) containing PPAR␣ binding sites. A distant upstream 5= untranslated region (Ϫ4723 to Ϫ4460, region 3 [R3]) of the FABP1 gene was amplified as a negative control with the primers 5=-TCTCACCCTCACCCTCAACT-3= (sense) and 5=-AATGCCCACCAACAGTAGACT-3= (antisense).
ELISA. The amounts of FABP1 present in HBV-infected serum or in non-HBV-infected serum were determined using an anti-human FABP1 ELISA kit (GWB-HFABP1; GeneWay Biotech, Inc., San Diego, CA) or a specific anti-mouse FABP1 ELISA kit (RFBP10; R&D Systems) according to the manufacturer's instructions.
Statistical analysis. The differences between two groups were analyzed by using a Student t test. All values are expressed as means Ϯ standard deviations (SD) from triplicate experiments. A P value of Ͻ0.05 was considered statistically significant.
RESULTS

HBV infection upregulates FABP1 expression.
The effect of HBV on FABP1 expression was first evaluated by qPCR and Western blot analysis in the stable HBV-producing hepatoma cell lines HepG2-HBV3 and HepG2.2.15 that had been proven to constitutively produce infectious HBV particles (6, 28) . Both FABP1 mRNA (Fig. 1A) and protein ( (Fig. 1C and D) . We also analyzed the expression of FABP1 in the sera of HBV-infected patients and HBV-Tg mice by ELISA. As expected, serum FABP1 levels were significantly higher in HBV-positive patients, with the HBV titer exceeding 10 7 copies/ml (Fig. 1E) , and mice than in their control groups (Fig. 1F) . Similarly, the expression of FABP1 was markedly upregulated in the liver tissues of HBV-Tg mice, relative to that of wild type (WT) mice ( Fig. 1G and H) . These data suggest that FABP1 is elevated under the condition of HBV infection and may play an important role in HBV infection-induced hepatic diseases.
HBx induces FABP1 gene expression. HBx appears to have the most pathogenic potential. To evaluate the effect of HBx on FABP1 gene expression, recombinant adenoviruses expressing HBx protein (Ad-HBx) or green fluorescent protein (GFP) control (Ad-GFP) were generated and used to infect cells, as we previously described (23) . The result showed that the expression of HBx significantly increased the FABP1 mRNA and protein levels in HepG2, Huh7, and Hep3B cells ( Fig. 2A and B) . Interestingly, transfection of the HBx mutant pRep-1.2HBV-X(-) into HepG2 cells reduced FABP1 expression compared to cells transfected with pRep-HBV ( Fig. 2C and D) . The fact that HBx constitutively upregulates FABP1 gene expression raised the question as to whether HBx would behave differently in the presence of fatty acid (FFA), a functional FABP1 inducer (10, 29) . Expectedly, the induction of FABP1 mRNA and protein expression was further increased in the FFA-treated HBx-expressing HepG2 cells (Fig. 2E  and F) . In addition, HBx-Tg mice also had a significant increase of FABP1 expression in sera and liver tissues compared to WT mice at the same age (Fig. 3) . Taken together, these data suggest that HBx is a critical regulator for FABP1 expression during HBV infection.
HBx facilitates HNF3␤, C/EBP␣, and PPAR␣ binding to FABP1 promoter. To determine whether HBx induces FABP1 transcription, a reporter plasmid pGL3B-255 containing the human FABP1 promoter sequence from positions Ϫ255 to ϩ50, a region known to possess maximum FABP1 promoter activity (21) , was cotransfected with Ad-HBx or Ad-GFP control into HepG2 cells. The luciferase assay revealed that the FABP1 promoter activity was markedly enhanced by the HBx protein (Fig.  4A) . Previous studies from our laboratory have demonstrated that FABP1 gene was regulated predominantly by liver-enriched transcription factors HNF3␤ and C/EBP␣ (21) , and a functional PPAR␣-responsive element was recently reported to play an important role in FABP1 gene regulation (30) . The putative binding sites of HNF3␤, C/EBP␣, and PPAR␣ on the FABP1 promoter were shown in Fig. 4B (upper panel) . To determine which elements were involved in HBx-related FABP1 gene transcription, we introduced mutations in the binding sites for HNF3␤, C/EBP␣, and PPAR␣. We found that mutations at either HNF3␤, C/EBP␣, or PPAR␣ binding site significantly decreased the HBxinduced promoter activity (Fig. 4B, lower panel) . Notably, mutations at all these three binding sites abolished its responsiveness to HBx-mediated FABP1 transcription. To further confirm that HBx-induced FABP1 expression was mediated through HNF3␤, C/EBP␣, or PPAR␣, we knocked down the expression of these transcription factors in Ad-HBx-or Ad-GFP-transduced HepG2 cells (Fig. 4C) and measured the FABP1 promoter activity. As shown in Fig. 4D , knockdown of either HNF3␤, C/EBP␣, or PPAR␣ reduced the HBx-mediated luciferase activities. Meanwhile, the expression of FABP1 at both mRNA (Fig. 4E ) and protein (Fig. 4F ) levels was also reduced significantly. Taken together, these results suggest that HNF3␤, C/EBP␣, and PPAR␣, through binding to their corresponding sites at the FABP1 promoter region, are essential for HBx-mediated FABP1 promoter activation and FABP1 transcription.
HBx increases HNF3␤ expression and interacts with C/EBP␣ and PPAR␣. To further investigate the mechanism underlying HBx-enhanced FABP1 expression, we examined whether HBx could directly affect the expression of HNF3␤, C/EBP␣, and PPAR␣. We found that ectopic expression of HBx in HepG2 cells increased HNF3␤ mRNA and protein levels but caused no significant changes in C/EBP␣ or PPAR␣ expression (Fig. 5A) . To assess whether HBx could physically interact with endogenous HNF3␤, C/EBP␣, or PPAR␣, we performed a coimmunoprecipitation study with HepG2 cells infected with recombinant virus encoding FLAG-tagged HBx. The results showed that FLAG-tagged HBx was immunoprecipitated with C/EBP␣ and PPAR␣ but not HNF3␤, and these interactions were further confirmed by reverse immunoprecipitation using HNF3␤, C/EBP␣, and PPAR␣ antibodies (Fig. 5B to D) . To test whether HBx binds FABP1 gene promoter, we performed a ChIP assay in Ad-HBx-infected HepG2 cells with specific antibodies against HNF3␤, C/EBP␣, PPAR␣, and FLAG-tagged HBx and PCR using the primers to amplify the fragments within the FABP1 promoter region corresponding to the C/EBP␣ and HNF3␤ binding sites (approximately Ϫ136 to Ϫ251) and the PPAR␣ binding site (approximately Ϫ36 to Ϫ155). The ChIP data indicated that the antibodies to HNF3␤, C/EBP␣, and PPAR␣ or the antibody to FLAG for capture of the FLAG-tagged HBx efficiently immunoprecipitated the corresponding FABP1 promoter region ( Fig. 5E and F) . These results suggests that HBx upregulated FABP1 transcription via enhancing the expression of HNF3␤ and interacting with C/EBP␣ and PPAR␣.
HBx-induced FABP1 gene expression causes lipid accumulation in HepG2 and HBx-Tg mice. To investigate the influence of HBx-mediated FABP1 gene activation on hepatic lipid metabolism at the cellular level, we treated HepG2 cells with a 0.5 mM FFA mixture (oleate/palmitate [2:1]) to induce an in vitro cellular steatosis. As revealed by Oil-Red-O staining (Fig. 6A) , FFA induced substantial lipid accumulation in HepG2 cells, and the percentage of positive cells among HBx expressing Ad-HBx cells was much higher than in the control Ad-GFP cells. In contrast, knockdown of FABP1 significantly prevented lipid accumulation in the cells. To evaluate whether the lipid accumulation in HepG2 cells resulted from differences in FABP1 expression, the protein levels of FABP1 were determined by Western blot analysis after the indicated treatments (Fig. 6B) . Consistently, the cellular TG contents were significantly higher in Ad-HBx cells than in Ad-GFP cells (Fig. 6C) , and siRNA-FABP1 treated cells markedly reduced TG accumulation. The results indicate that FABP1 expression level is correlated with the extent of hepatic steatosis.
To further confirm our findings under physiologic conditions, we investigated the hepatic lipid content in the liver tissues of HBx-Tg mice under HFD-induced hepatic steatosis. To overcome drawbacks of short-time action and lack of regenerating ability of siRNA and to permit robust inducible RNAi mediated FABP1 silencing, lentiviral LV-FABP1-shRNA was generated. The efficiencies of infection were observed under fluorescence microscope (Fig. 7A) , and gene silencing in mouse liver were determined in Fig. 7B . After 8 weeks of HFD induction, HBx mice developed a more prominent fatty liver phenotype featuring an enlarged and light-colored liver caused by extensive fat accumulation compared to WT mice at the same age (Fig. 7C) . In contrast, knockdown of the mouse FABP1 gene significantly prevented lipid accumulation in the liver (Fig. 7C) . Consistently, liver weights and liver TG contents were significantly higher in HBx-Tg mice than in WT mice and were reduced by LV-FABP1-shRNA treatment ( Fig. 7D and E) . We then examined the histologic changes of the hepatic sections. Similar to our findings in HepG2 cells, H&E and Oil-Red-O staining of liver sections revealed the presence of diffuse intracellular lipid droplets in HBx-Tg mice compared to the WT mice, and treatment of the LV-FABP1-shRNA markedly reduced lipid accumulation (Fig. 7F) .
DISCUSSION
Nonalcoholic fatty liver disease (NAFLD) has attracted considerable attention due to its high morbidity. This disease features an excessive triglyceride accumulation in hepatocytes (31) . Prolonged NAFLD is associated with steatohepatitis, a condition that can result in end-stage liver diseases (32, 33) . Increasing evidence has indicated that chronic HBV infection, as well as HCV infection, is associated with hepatic steatosis through alterations in lipid metabolism (2, 3) . Among the four HBV-encoding proteins, the HBV X protein (HBx) apparently has the most pathogenic potential involving in HBV infection, replication, apoptosis, cell proliferation, DNA damage, and even hepatocarcinogenesis (34) (35) (36) . Thus, we hypothesized that HBx may be involved in HBVinduced hepatic steatosis.
To address this hypothesis, we first investigated the effect of HBV on FABP1 expression in HBV-producing hepatoma cell lines and in the sera of HBV-infected patients and HBV-Tg mice. Our results showed that FABP1 was upregulated by HBV. We further observed that FABP1 was activated markedly in HBx-expressing hepatoma cell lines and HBx-Tg mice. Thus, we conclude that HBx is able to upregulate FABP1 in hepatoma cells, which may contribute to the development of HBV-related hepatic steatosis. Numerous studies have shown that HBx does not bind DNA directly, but it can transactivate multiple cellular promoters by interacting with nuclear transcription factors (34) , such as TFIIB (37) , RXR (38) , AP1 (39) , and NF-B (40). In our previous report, we identified that the Ϫ255/ϩ50 fragment contained the core region of the FABP1 promoter (21) . Results from this study showed that HBx was indeed able to activate the Ϫ255/ϩ50 region in a dose-dependent manner. Intriguingly, we also found that liver-enriched transcription factors HNF3␤ and C/EBP␣ elements were present in the Ϫ255/ϩ50 FABP1 promoter region (21) .
HNF3␤ and C/EBP␣ belong to the liver-enriched transcription factors families. HNF3␤ belongs to the HNF-3 gene family, which includes three proteins (HNF3␣, HNF3␤, and HNF3␥) that mediate hepatocyte-enriched transcription of numerous genes necessary for organ function (41) . C/EBP␣ belongs to the C/EBP family, which is composed of six related proteins that belong to the larger family of basic region leucine zipper (bZIP) transcription factors (42) . High expression levels of human C/EBP␣ have been found in liver and other organs (43) . C/EBP␣ is involved in diverse physiological functions in liver biology that include energy metabolism (44) , liver regeneration (45) , cellular differentiation The ratio of FABP1 protein levels in the treated cells relative to that in the control Ad-GFPϩNCϩBSA cells was calculated densitometrically after normalization to the level of ␤-actin. Values are means Ϯ the SD (n ϭ 3). (C) The triglyceride content was measured in HepG2 cell lysates with the indicated treatments using a commercially assay kit, as described in Materials and Methods. Triglyceride levels were normalized to the protein concentration (g/mg) and is given as means Ϯ the SD of three separate experiments. *, P Ͻ 0.05. (46) , and cell cycle control (42) . PPAR␣, a lipid-sensor nuclear factor, is highly expressed in liver tissue (47) and plays a key role in hepatic lipid metabolism. PPAR␣ was reported to lower plasma TG by decreasing production of very-low-density lipoproteins, enhancing fatty acid oxidation and stimulating clearance of TGrich lipoproteins (48) . Mice deficient in PPAR␣ are reported to be prone to massive hepatic lipid accumulation, hypercholesterolemia, and hypertriglyceridemia (49) . Thus, we sought to deter- mine whether HNF3␤, C/EBP␣, and PPAR␣ were involved in HBx-enhanced FABP1 expression. Our data demonstrated that HBx failed to activate the FABP1 promoter when either the HNF3␤, C/EBP␣, or PPAR␣ binding site in the promoter was mutated and that the promoter activity of FABP1 was reduced when either HNF3␤, C/EBP␣, or PPAR␣ was knocked down by the respective siRNA. Meanwhile, the expression levels of FABP1 induced by HBx were also downregulated. Moreover, HBx turned out to induce FABP1 gene expression by upregulating the HNF3␤ expression level, but not those of C/EBP␣ or PPAR␣. Furthermore, HBx interacted with C/EBP␣ or PPAR␣, but not HNF3␤, leading to the enhanced transcriptional activity of C/EBP␣ and PPAR␣. Accordingly, we validated by ChIP assay that HBx was able to indirectly bind to the promoter of FABP1 by HNF3␤, C/EBP␣, and PPAR␣. Therefore, it is conceivable that HBx activates the FABP1 promoter through HNF3␤, C/EBP␣, and PPAR␣.
In functional studies, we elucidated the important role of FABP1 in governing hepatic lipid metabolism using a HepG2 in vitro cellular steatosis model and an in vivo dietary-fat-overloading mouse model. The observation that FFA-induced lipid accumulation was dramatically reduced in HepG2 cells and that fat accumulation was diminished in HFD-treated mice supports a protective role of FABP1 deficiency in HBx-induced hepatic steatosis.
In summary, we demonstrate that HBx promotes hepatic lipid accumulation through upregulating FABP1 that involves HNF3␤, C/EBP␣, and PPAR␣ in the development of HBV-induced NAFLD. An interaction between HBx and FABP1 may be a key central driver for pathogenesis of hepatic steatosis. The present data may provide a potential therapeutic option to protect HBVinfected livers from HBx-induced lipid deposition and deterioration of hepatic functions by inhibition of FABP1 expression.
